US regulators Monday approved BristolMyers Squibb Cos Opdivo for advanced skin cancer the latest drug to reach the market in the emerging field of cancer immunotherapy The decision by the Food and Drug Administration means BristolMyers now has two drugs on the market that work by unleashing the bodys immune system to attack tumors helping to solidify the companys lead in an area of cancer treatment that has drawn wide interest across the pharmaceutical industry